Evidence map›Paper›PMID 33809389›Full record

ArticleAntioxidants (Basel, Switzerland)2021

A Novel Vasoactive Peptide "PG1" from Buffalo Ice-Cream Protects from Angiotensin-Evoked High Blood Pressure.

Albino Carrizzo, Manuela Giovanna Basilicata, Giacomo Pepe, Kasper K Sørensen, Michele Ciccarelli, Veronica Di Sarno, Antonio Damato, Eleonora Venturini, Anna Borrelli, Simona Musella and 5 more

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Healthberry 865Antioxidants (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Albino CarrizzoDepartment of Medicine and Surgery, University of Salerno, 84081 Baronissi, SA, Italy.ORCID 0000-0003-2689-0008
Manuela Giovanna BasilicataDepartment of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy.
Giacomo PepeDepartment of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy.
Kasper K SørensenDepartment of Chemistry, University of Copenhagen, 1870 Frederiksberg, Denmark.
Michele CiccarelliDepartment of Medicine and Surgery, University of Salerno, 84081 Baronissi, SA, Italy.ORCID 0000-0003-2379-1960
Veronica Di SarnoDepartment of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy.
Antonio DamatoIRCCS Neuromed, Vascular Pathophysiology Unit, 86077 Pozzilli, IS, Italy.
Eleonora VenturiniIRCCS Neuromed, Vascular Pathophysiology Unit, 86077 Pozzilli, IS, Italy.
Anna BorrelliUniversity Hospital "San Giovanni di Dio e Ruggi D'Aragona", via S. Leonardo, 1, 84131 Salerno, SA, Italy.
Simona MusellaEuropean Biomedical Research Institute of Salerno, 84131 Salerno, SA, Italy.ORCID 0000-0001-8312-4241
Mario AbateDepartment of Medicine and Surgery, University of Salerno, 84081 Baronissi, SA, Italy.ORCID 0000-0003-0578-4812
Paola Di PietroDepartment of Medicine and Surgery, University of Salerno, 84081 Baronissi, SA, Italy.ORCID 0000-0003-1327-1961
Carmine OstacoloDepartment of Pharmacy, University of Naples Federico II, 80131 Napoli, NA, Italy.ORCID 0000-0003-3715-8680
Pietro CampigliaDepartment of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy.ORCID 0000-0002-1069-2181
Carmine VecchioneDepartment of Medicine and Surgery, University of Salerno, 84081 Baronissi, SA, Italy.
University of Salerno · ITIstituto Neurologico Mediterraneo · ITEuropean Biomedical Research Institute of Salerno · ITOspedali Riuniti San Giovanni di Dio e Ruggi d'Aragona · ITUniversity of Copenhagen · DKUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundArterial hypertension is the most important risk factor for cardiovascular diseases, myocardial infarction, heart failure, renal failure and peripheral vascular disease. In the last decade, milk-derived bioactive peptides have attracted attention for their beneficial cardiovascular properties.

methodsHere, we combined in vitro chemical assay such as LC-MS/MS analysis of buffalo ice cream, ex vivo vascular studies evaluating endothelial and smooth muscle responses using pressure myograph, and translational assay testing in vivo the vascular actions of PG1 administration in murine models.

resultsWe demonstrate that a novel buffalo ice-cream-derived pentapeptide "QKEPM", namely PG1, is a stable peptide that can be obtained at higher concentration after gastro-intestinal digestions (GID) of buffalo ice-cream (BIC). It owns potent vascular effect in counteract the effects of angiotensin II-evoked vasoconstriction and high blood pressure levels. Its effects are mediated by the inhibitory effect on AT1 receptor leading to a downregulation of p-ERK½/Rac1-GTP and consequent reduction of oxidative stress.

conclusionsThese results strongly candidate PG1, as a novel bioactive peptide for the prevention and management of hypertension, thus expanding the armamentarium of preventive strategies aimed at reducing the incidence and progression of hypertension and its related cardiovascular complications.

Indexed as

angiotensin IIcardiovascularnatural derived-peptide

Identifiers

PMID33809389
PMCPMC8002072
OpenAlexW3138117634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.